Hematology & Oncology Doctors in Lewiston, ME Accepting Medicare

6 Hematology & Oncology doctors found. Showing 1 - 6

Nicholette Erickson, MD Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 12 High St Ste 6, Lewiston, ME 04240 Phone: 207-795-2935

Dr. David Clark Caldwell, M.D. Internal Medicine - Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 12 High St, Ste 205, Lewiston, ME 04240 Phone: 207-795-2935    Fax: 207-795-2319

Donna Thompson, Internal Medicine - Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 300 Main St, Lewiston, ME 04240 Phone: 207-795-5709

Dr. Eric T. Lubiner, D.O. Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 93 Campus Ave I2 Wing, Lewiston, ME 04240 Phone: 207-777-4420    Fax: 207-777-4430

Na Liu, MD Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 93 Campus Ave, Lewiston, ME 04240 Phone: 207-777-4420    Fax: 207-777-4430

Dr. Gregory S Emmons, DO Internal Medicine - Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 93 Campus Ave, Lewiston, ME 04240 Phone: 207-777-4320    Fax: 207-777-4330

News Archive

Lund researchers discover how E. coli bacteria target and degrade MYC oncogene

Scientists at Lund University have discovered how E. coli bacteria target and degrade the well-known oncogene MYC, which is involved in many forms of cancer.

Young cancer survivors more likely to be current cigarette smokers

Researchers at The University of Texas Medical Branch at Galveston have found that cancer survivors who were diagnosed at adolescent and young adult ages are more likely to be current cigarette smokers than people who have not had cancer. The findings of this study are currently available in Cancer.

MRA therapy does not improve outcome in heart attack patients without heart failure

Heart attack patients without heart failure derive no benefit from the addition of mineralocortoid receptor antagonists (MRA), to standard therapy, results of the ALBATROSS study show.

CEL-SCI commences clinical study of LEAPS-H1N1 treatment for hospitalized patients

CEL-SCI Corporation, a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases and a late-stage oncology company, announced today the start of the Company's first clinical study for hospitalized H1N1 patients at The Johns Hopkins University School of Medicine (Johns Hopkins).

Read more Medical News

› Verified 5 days ago